Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NUVB Nuvation Bio, Inc.

Post-Mkt 03-03 16:18:14 EST

4.36

-1.48

-25.34%

盘后4.28

-0.08-1.83%

16:16 EST

High4.82	Low4.16	Vol18.31M
Open4.81	D1 Closing5.84	Amplitude11.30%
Mkt Cap1.49B	Tradable Cap1.01B	Total Shares342.83M
T/O80.36M	T/O Rate7.92%	Tradable Shares231.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":4.36,"timestamp":1772571600000,"preClose":5.84,"halted":0,"volume":18308278,"hourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.36,"latestTime":"16:16 EST","volume":248470,"amount":1083321.99437,"timestamp":1772572565557,"change":-0.08,"changeRate":-0.018349,"amplitude":0.018349},"delay":0,"changeRate":-0.2534246575342465,"floatShares":231046340,"shares":342833433,"eps":-0.640012,"marketStatus":"Post-Mkt","change":-1.48,"latestTime":"03-03 16:18:14 EST","open":4.81,"high":4.82,"low":4.16,"amount":80357064.360858,"amplitude":0.113014,"askPrice":4.51,"askSize":100,"bidPrice":4.2,"bidSize":170,"shortable":0,"etf":0,"ttmEps":-0.640012,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772586000000},"marketStatusCode":4,"adr":0,"exchange":"NYSE","adjPreClose":5.84,"preHourTrading":{"tag":"盘前","latestPrice":4.74,"preClose":5.84,"latestTime":"09:29 EST","volume":39479,"amount":193067.03566700002,"timestamp":1772548154542,"change":-1.1,"changeRate":-0.188356,"amplitude":0.138699},"postHourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.36,"latestTime":"16:16 EST","volume":248470,"amount":1083321.99437,"timestamp":1772572565557,"change":-0.08,"changeRate":-0.018349,"amplitude":0.018349},"volumeRatio":3.828412,"impliedVol":1.8441,"impliedVolPercentile":0.8845},"requestUrl":"/m/hq/s/NUVB","defaultTab":"news","newsList":[{"id":"2616327706","title":"Nuvation Bio Plunges on Higher Discontinuations in Ibtrozi Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2616327706","media":"Dow Jones","labels":["productRelease"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2616327706?lang=en_us&edition=fundamental","pubTime":"2026-03-04 01:13","pubTimestamp":1772557980,"startTime":"0","endTime":"0","summary":"Shares of Nuvation Bio fell after the oncology company said early sales of Ibtrozi, a lung-cancer drug that represents its only source of product revenue, showed a high rate of discontinuations.The stock tumbled 26%, to $4.33, midday Tuesday. The stock has gained nearly one-and-a-half times its value in the past year.Chief Commercial Officer Colleen Sjogren told analysts on a Monday call that three-quarters of Ibtrozi discontinuations from patients in the company's Nuvation Connect support program came from later-line populations.She said it isn't unusual that the majority of patients early in an oncology launch are in need of a third or fourth medicine, which translates to a lower response and duration of treatment. Dicontinuations are expected to fall as the company moves Ibtrozi further up in the treatment paradigm, she said.\"By the end of 2026, we expect to see a more direct correlation between growth in new patient starts and growth in our revenue, as a larger portion of active pa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Nuvation Bio Plunges on Higher Discontinuations in Ibtrozi Launch","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2616137686","title":"Nuvation Bio Is Maintained at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2616137686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616137686?lang=en_us&edition=fundamental","pubTime":"2026-03-04 03:27","pubTimestamp":1772566020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 14:27 ET (19:27 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2616090322","title":"Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616090322","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616090322?lang=en_us&edition=fundamental","pubTime":"2026-03-04 00:30","pubTimestamp":1772555412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report) and Nu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-scholar-rock-holding-srrk-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-scholar-rock-holding-srrk-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","LABU","NUVB","BK4588","LU0029874061.USD","SRRK","XLV","LU0128526141.USD","BK4139","BK4581","BK4007","XBI","HCSG"],"gpt_icon":0},{"id":"2616210173","title":"Nuvation Bio falls -26.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616210173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616210173?lang=en_us&edition=fundamental","pubTime":"2026-03-03 23:06","pubTimestamp":1772550412,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) is down -26.1%, or -$1.52 to $4.32. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-26-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-falls-26-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"1180923020","title":"Stock Track | Nuvation Bio Plummets 25.26% Intraday on Earnings Miss and Analyst Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1180923020","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180923020?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:44","pubTimestamp":1772549076,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. (NUVB) shares plummeted 25.26% during intraday trading on Tuesday, marking a significant decline for the biotechnology stock.The sharp drop follows the company's recent...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NUVB"],"gpt_icon":0},{"id":"2616362328","title":"RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2616362328","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616362328?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:57","pubTimestamp":1772542679,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) has an average rating of buy and mean price target of $11.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2616347777","title":"Truist Financial Keeps Their Buy Rating on Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347777","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347777?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:37","pubTimestamp":1772541468,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Gregory Renza reiterated a Buy rating on Nuvation Bio today and set a price target of $12.00. Renza covers the Healthcare ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB"],"gpt_icon":0},{"id":"2616347718","title":"RBC Capital Remains a Buy on Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347718?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:29","pubTimestamp":1772540990,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on Nuvation Bio yesterday and set a price target of $13.00. The company’s shares closed...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310800379.SGD","BK4207","NUVB","LU0029864427.USD","BK4007","LU0708994859.HKD","LU0128525929.USD","LU1267930573.SGD"],"gpt_icon":0},{"id":"2616344310","title":"H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344310?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:37","pubTimestamp":1772537833,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Nuvation Bio, with a price target of $17.00. Burns covers ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB"],"gpt_icon":0},{"id":"1146990318","title":"Stock Track | Nuvation Bio Plunges 14.04% in Pre-market Trading on Quarterly Earnings Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1146990318","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146990318?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:22","pubTimestamp":1772533353,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. (NUVB) shares plummeted 14.04% in pre-market trading on Tuesday. The sharp decline follows the biotechnology company's recent fourth-quarter earnings report.The company reported a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NUVB"],"gpt_icon":0},{"id":"1122925666","title":"Stock Track | Nuvation Bio Plunges 10.79% After-Hours on Quarterly Earnings Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1122925666","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122925666?lang=en_us&edition=fundamental","pubTime":"2026-03-03 12:07","pubTimestamp":1772510830,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. (NUVB) shares experienced a significant 24-hour plunge of 10.79%, with the sharp decline concentrated in the extended trading session following the release of the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NUVB"],"gpt_icon":0},{"id":"1128251709","title":"Stock Track | Nuvation Bio Plunges 6.68% After-Hours on Quarterly Earnings Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1128251709","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128251709?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:38","pubTimestamp":1772491123,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. (NUVB) shares experienced a significant after-hours plunge of 6.68% on Monday. The sharp decline followed the release of the company's fourth-quarter financial results.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NUVB"],"gpt_icon":0},{"id":"2616439369","title":"Earnings Flash (NUVB) Nuvation Bio Posts Q4 Loss $-0.11, vs. FactSet Est of Loss of $-0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2616439369","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616439369?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:24","pubTimestamp":1772486694,"startTime":"0","endTime":"0","summary":"Earnings Flash (NUVB) Nuvation Bio Posts Q4 Loss $-0.11, vs. FactSet Est of Loss of $-0.09","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUVB"],"gpt_icon":0},{"id":"2616436913","title":"Nuvation Bio Publishes Corporate Presentation on IBTROZI ROS1 Lung Cancer and Safusidenib IDH1 Glioma Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616436913","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616436913?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:22","pubTimestamp":1772486547,"startTime":"0","endTime":"0","summary":"Nuvation Bio Inc. highlighted its oncology portfolio, including IBTROZI , a ROS1 inhibitor approved in the U.S., Japan and China for advanced ROS1-positive non-small cell lung cancer. The company reported 2025 U.S. net product revenue of $24.7 million and 432 new patient starts since launch, and said it is enrolling the TRUST-IV study in early-stage ROS1-positive NSCLC. The presentation also outlined development of safusidenib, an IDH1 inhibitor being evaluated in the pivotal SIGMA study for high-risk or high-grade IDH1-mutant astrocytoma, alongside a non-pivotal cohort for grade 3 IDH1-mutant oligodendroglioma. Nuvation Bio also described ongoing evaluation of preclinical candidates from its Drug-Drug Conjugate platform and reported a pro forma cash balance of approximately $589 million. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL5ZlwK6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2616236621","title":"Nuvation Bio posts Q4 collaboration and license agreements revenue of USD 26.2 million, up 4.6x","url":"https://stock-news.laohu8.com/highlight/detail?id=2616236621","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616236621?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:08","pubTimestamp":1772485685,"startTime":"0","endTime":"0","summary":"Nuvation Bio posts Q4 collaboration and license agreements revenue of USD 26.2 million, up 4.6x               Nuvation Bio reported Q4 2025 net product revenue of USD 15.7 million, reflecting U.S. sal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL67yjds:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648000940.SGD","LU1201861249.SGD","LU0130102774.USD","LU1989764664.SGD","IQV","LU0528227936.USD","BK4585","LU0477156953.USD","LU0477156797.USD","LU1791710582.SGD","LU0130518102.USD","BK4007","LU1989764748.USD","LU1261432733.SGD","LU1791710400.SGD","BK4530","LU0130103400.USD","BK4588","LU0130517989.USD","NUVB","LU0198837287.USD","LU1201861165.SGD","LU0980610538.SGD","BK4121","LU0648001328.SGD","LU0882574055.USD"],"gpt_icon":0},{"id":"2616366472","title":"Nuvation Bio Q4 EPS $(0.11) Misses $(0.09) Estimate, Sales $41.865M Beat $37.326M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2616366472","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616366472?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:07","pubTimestamp":1772485642,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 26.67 percent increase over losses of $(0.15) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/50983519/nuvation-bio-q4-eps-0-11-misses-0-09-estimate-sales-41-865m-beat-37-326m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nuvation Bio Q4 EPS $(0.11) Misses $(0.09) Estimate, Sales $41.865M Beat $37.326M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2616366179","title":"BRIEF-Nuvation Bio Q4 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2616366179","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616366179?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:05","pubTimestamp":1772485546,"startTime":"0","endTime":"0","summary":"BRIEF-Nuvation Bio Q4 EPS USD -0.11\n\n\nMar 02 (Reuters) - Nuvation Bio Q4 income from pperations USD -34.037 million.\n\nQ4 net income USD -36.592 million\nQ4 pretax profit USD -36.592 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nPLXF72978:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2616366939","title":"Nuvation Bio Q4 Pretax Profit USD -36.592 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616366939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616366939?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:05","pubTimestamp":1772485502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nPLXF72978:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2616400366","title":"Press Release: Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2616400366","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616400366?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:05","pubTimestamp":1772485500,"startTime":"0","endTime":"0","summary":"Successfully started 216 patients on IBTROZI  in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025. Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and Japan. Published positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant glioma. Strong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025. commercialize taletrectinib for the treatment of ROS1+ NSCLC in Europe,the Middle East, North Africa, Russia, Turkey, Canada, Australia, New","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","NUVB","BK4007","BK4232","BK4022"],"gpt_icon":0},{"id":"2614889723","title":"Nuvation Bio (NUVB) Is Up 8.6% After Advancing Safusidenib Into Phase 3 Brain Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2614889723","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614889723?lang=en_us&edition=fundamental","pubTime":"2026-02-28 13:28","pubTimestamp":1772256516,"startTime":"0","endTime":"0","summary":"Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 and grade 4 IDH1‑mutant astrocytoma after standard‑of‑care treatment.\nThis shift into a registrational Phase 3 setting materially advances safusidenib within Nuvation Bio’s pipeline, potentially reshaping the company’s role in treating aggressive IDH1‑mutant brain tumors.\nNext, we’ll examine how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-is-up-86-after-advancing-safusidenib-into","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-is-up-86-after-advancing-safusidenib-into","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NUVB"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0696},{"period":"1month","weight":0.1145},{"period":"3month","weight":-0.2182},{"period":"6month","weight":0.854},{"period":"1year","weight":1.9645},{"period":"ytd","weight":-0.3482}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.099824},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.044723},{"month":3,"riseRate":0.5,"avgChangeRate":0.127525},{"month":4,"riseRate":0.4,"avgChangeRate":0.005292},{"month":5,"riseRate":0.6,"avgChangeRate":0.002702},{"month":6,"riseRate":0.2,"avgChangeRate":-0.090917},{"month":7,"riseRate":0.6,"avgChangeRate":0.065913},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction